Tothfalusi L, Endrenyi L, Garcia Arieta A
Clin Pharmacokinet. 2009; 48(11):725-43.
PMID: 19817502
DOI: 10.2165/11318040-000000000-00000.
Fuhr U
Eur J Clin Pharmacol. 2007; 63(10):897-9.
PMID: 17684737
DOI: 10.1007/s00228-007-0357-6.
Deng L, Wang F, Li H
Eur J Clin Pharmacol. 2005; 61(11):831-6.
PMID: 16283275
DOI: 10.1007/s00228-005-0042-6.
Depre M, Van Hecken A, Oeyen M, De Lepeleire I, Laethem T, Rothenberg P
Eur J Clin Pharmacol. 2005; 61(5-6):341-6.
PMID: 15983826
DOI: 10.1007/s00228-005-0907-8.
Kondo S, Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Inoue Y
Eur J Clin Pharmacol. 2005; 61(3):185-8.
PMID: 15776275
DOI: 10.1007/s00228-005-0904-y.
Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients.
Hermann M, Asberg A, Christensen H, Reubsaet J, Holdaas H, Hartmann A
Eur J Clin Pharmacol. 2005; 61(1):59-62.
PMID: 15711834
DOI: 10.1007/s00228-004-0874-5.
Effect of menthol on the pharmacokinetics and pharmacodynamics of felodipine in healthy subjects.
Gelal A, Balkan D, Ozzeybek D, Kaplan Y, Gurler S, Guven H
Eur J Clin Pharmacol. 2004; 60(11):785-90.
PMID: 15592925
DOI: 10.1007/s00228-004-0847-8.
Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism.
Araki K, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Inoue Y
Eur J Clin Pharmacol. 2004; 60(6):427-30.
PMID: 15232663
DOI: 10.1007/s00228-004-0789-1.
Influence of menthol on caffeine disposition and pharmacodynamics in healthy female volunteers.
Gelal A, Guven H, Balkan D, Artok L, Benowitz N
Eur J Clin Pharmacol. 2003; 59(5-6):417-22.
PMID: 12915954
DOI: 10.1007/s00228-003-0631-1.
Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers.
Peng W, Li H, Zhou H
Eur J Clin Pharmacol. 2003; 59(3):237-41.
PMID: 12756512
DOI: 10.1007/s00228-003-0596-0.
Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.
Dingemanse J, Meyerhoff C, Schadrack J
Br J Clin Pharmacol. 2002; 53(5):485-91.
PMID: 11994054
PMC: 1874359.
DOI: 10.1046/j.1365-2125.2002.01587.x.
Therapeutic drug monitoring databases for postmarketing surveillance of drug-drug interactions.
Gex-Fabry M, Balant L
Drug Saf. 2001; 24(13):947-59.
PMID: 11735651
DOI: 10.2165/00002018-200124130-00002.
Clinical-pharmacological strategies to assess drug interaction potential during drug development.
Kuhlmann J, Muck W
Drug Saf. 2001; 24(10):715-25.
PMID: 11676300
DOI: 10.2165/00002018-200124100-00001.
Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects.
Sitsen J, Maris F, Timmer C
Eur J Drug Metab Pharmacokinet. 2001; 26(1-2):109-21.
PMID: 11554425
DOI: 10.1007/BF03190384.
Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers.
Stass H, Sachse R
Clin Pharmacokinet. 2001; 40 Suppl 1:71-6.
PMID: 11352445
DOI: 10.2165/00003088-200140001-00010.
Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
Stass H, Bottcher M, Ochmann K
Clin Pharmacokinet. 2001; 40 Suppl 1:39-48.
PMID: 11352441
DOI: 10.2165/00003088-200140001-00006.
Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers.
Stass H, Wandel C, Delesen H, Moller J
Clin Pharmacokinet. 2001; 40 Suppl 1:27-32.
PMID: 11352439
DOI: 10.2165/00003088-200140001-00004.
Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? FDA Biopharmaceutics Coordinating Committee.
Williams R, Adams W, Chen M, Hare D, Hussain A, Lesko L
Eur J Drug Metab Pharmacokinet. 2000; 25(1):7-12.
PMID: 11032082
DOI: 10.1007/BF03190049.
Steady-state pharmacokinetics of lithium in healthy volunteers receiving concomitant meloxicam.
Turck D, Heinzel G, Luik G
Br J Clin Pharmacol. 2000; 50(3):197-204.
PMID: 10971303
PMC: 2014978.
DOI: 10.1046/j.1365-2125.2000.00241.x.
Lack of interaction between thioctic acid, glibenclamide and acarbose.
Gleiter C, Schreeb K, Freudenthaler S, Thomas M, Elze M, Potthast H
Br J Clin Pharmacol. 1999; 48(6):819-25.
PMID: 10594485
PMC: 2014305.
DOI: 10.1046/j.1365-2125.1999.00097.x.